Logo for AIM ImmunoTech Inc

AIM ImmunoTech Investor Relations Material

Latest events

Logo for AIM ImmunoTech Inc

Q3 2024

AIM ImmunoTech
Logo for AIM ImmunoTech

Q3 2024

15 Nov, 2024
Logo for AIM ImmunoTech

Q2 2024

16 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from AIM ImmunoTech Inc

Access all reports
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma, Inc., is an immuno-pharmaceutical company dedicated to the research and development of therapeutics for the treatment of multiple types of cancers, viral diseases, and immune-deficiency disorders. The company's leading product candidate is Ampligen, a drug composed of macromolecular ribonucleic acid molecules aimed at treating chronic fatigue syndrome (CFS). Ampligen is also under development for various cancer types, including renal cell carcinoma, malignant melanoma, and others, as well as for conditions like Hepatitis B, HIV, COVID-19, and post-COVID conditions. Another key product is Alferon N Injection, an injectable formulation of natural alpha interferon for treating human papillomavirus (HPV) and genital warts. The company is headquartered in Ocala, Florida, and its shares are listed on the NYSE.